1 / 25

Risk of colorectal cancer in patients taking statins and NSAIDS

Risk of colorectal cancer in patients taking statins and NSAIDS. Dr Yana Vinogradova, Prof Julia Hippisley-Cox, Dr Carol Coupland and Prof Richard Logan Divisions of Primary Care, and Epidemiology & Public Health, University of Nottingham, UK. UEGW Plenary session Berlin 23 rd October 2006.

talasi
Download Presentation

Risk of colorectal cancer in patients taking statins and NSAIDS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Risk of colorectal cancer in patients taking statins and NSAIDS Dr Yana Vinogradova, Prof Julia Hippisley-Cox, Dr Carol Coupland and Prof Richard Logan Divisions of Primary Care, and Epidemiology & Public Health, University of Nottingham, UK UEGW Plenary session Berlin 23rd October 2006

  2. Background to CRC statin analysis • Evidence from animal models and other lab data that statins might prevent cancer • A meta-analysis of 26 large statin trials found no difference in incidence of CRC but limited power as only 4 reported CRC data • Recent case control study (Poynter NEJM 2005) found a 47% reduction in CRC risk

  3. Meanwhile • Mass of observational and experimental evidence that aspirin and traditional NSAIDs lower CRC risk • Trials of Colorectal adenoma prevention with COX2 show a 40-50% reduction in recurrence (Bertagnolli, Arber NEJM August 2006) • Little observational data available on risk of colorectal cancer in COX2 users

  4. Study population: QRESEARCH database • Currently largest primary care database in the UK • 537 general practices across the UK • > 9 million patients including those who have died or left, as well as patients still registered • > 30 million person-years of observation

  5. General Practice data collection:

  6. Data source: QRESEARCH database • Derived from GP clinical records • Patient level consolidated database • Anonymised data • Longitudinal data for 15+ years • Validated against external and internal measures

  7. Study design & setting • Nested case control study • Study period Jan 1995-July 2005 • Cases were incident colorectal cancer patients • 5 controls matched by • Age • Sex • Practice • Calendar year

  8. Exposure assessment : • statins, NSAIDs, Cox2 Inhibitors and aspirinprescriptions analysis restricted to subjects with +4yrs of prescribing data • any use: • at least 1 script in 13-48 months prior to the index date (date of diagnosis in the case) • number of prescriptions: • 1 script only • 2-12 scripts • 13-24 scripts • 25 or more scripts

  9. Statistical analysis • Conditional logistic regression • Odds ratios + 95% CI • Unadjusted & adjusted

  10. Study Sample:

  11. Comorbidity in CRC cases and controls:

  12. Body mass index Less than 25 kg/m2 25 to 29.9 kg/m2 30 kg/m2 or more BMI not recorded Smoking status Non-smoker Smoker not recorded Socio-economic status (Townsend score for post code) quintiles Morbidities IHD (±MI) Diabetes High BP Osteoarthritis Colitis Rheumatoid arthritis Stroke Confounding factors :

  13. Any use in 13-48 months prior to the index date

  14. Risks with prolonged prescribing in 13-48 months prior to index date • 25 or more statin scripts: adj. OR 1.13 (0.91 - 1.41) • 25 or more COX-2 scripts: adj. OR 0.34 (0.14 - 0.85) • 25 or more NSAID scripts: adj. OR 0.76 (0.60 – 0.95) • 25 or more Aspirin scripts: adj. OR 0.88 (0.74 – 1.05)

  15. Conclusions • Prolonged statin use is not associated with reduced risk of colorectal cancer • Prolonged NSAID and Cox2 inhibitor use is associated with reduced risk of colorectal cancer

  16. Implications • No increase in risk of colorectal cancer with cholesterol lowering • Supports role for COX 2 inhibitors in secondary / tertiary prevention of colorectal cancer

  17. Methodological strengths • Large sample size and representative population • Data electronically collected – unlikely misclassification bias • Data collected before the diagnosis – no recall bias • Excluded prescriptions 12 months prior to cancer diagnosis

  18. Use of individual statins

  19. Baseline characteristics:

  20. Study sample:

  21. Rel Risk of CRC with aspirin use by recency, duration and dose in UK GPRD (Garcia Rodriguez Epidemiology 2001)

More Related